Scheme document published for the £16.7 million recommended cash acquisition of Yourgene Health by Novacyt
July 2023
Yourgene Health is an AIM listed, Manchester based international molecular diagnostics group which develops integrated genomic technologies and services enabling precision medicine. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group’s flagship products include non-invasive prenatal tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.
Novacyt is an AIM listed international diagnostics business headquartered in Vélizy in France, delivering a broad portfolio of in vitro and molecular diagnostic tests for a wide range of infectious diseases, enabling faster, more accurate, accessible testing to improve healthcare outcomes.
The Company provides customers with a seamless sample-to-result workflow using its integrated and scalable instrumentation/solutions. The Company specialises in the design, manufacture, and supply of real-time PCR kits, reagents and a full range of laboratory and qPCR instrumentation for molecular biology research and clinical use.
Novacyt offers one of the world’s most varied and comprehensive range of qPCR assays, covering human, veterinary, biodefence, environmental, agriculture and food testing.
Publication of the Scheme Document
Having first started working with Yourgene by helping them with the production of their annual report in March 2022, the Perivan shareholder communications team was delighted to work with Addleshaw Goddard who provided legal advice on the production of the Scheme and associated ancillary documents in relation to the acquisition, which were successfully published and posted to qualifying shareholders on 27th July 2023.
For further information, click here.
Perivan specialise in producing and publishing financial documents relating to shareholder and investor communications for quoted companies, private companies, and open and closed-ended funds.
